DelveInsight’s “Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Discover Key Insights into the Functional Dyspepsia Market with DelveInsight’s In-Depth Report @ Functional Dyspepsia Prevalence
Key Takeaways from the Functional Dyspepsia Market Report
- In January 2026, Phase III trials of Aurantii Fructus Immaturus flavonoid tablets (AFIF) demonstrated efficacy and acceptable safety in Functional Dyspepsia patients in a multicenter, randomized, double-blind, placebo-controlled trial conducted in China, supporting its potential as a new herbal-derived prokinetic/visceral modulatory option.
- In February 2025, long-term (1-year) open-label extension data for itopride in Functional Dyspepsia showed the drug was well tolerated, with over 70% of patients remaining symptom-free or markedly improved, reinforcing its role as a sustained prokinetic therapy.
- In the assessment done by DelveInsight, the United States accounted for approximately 50% of the prevalent cases of Functional Dyspepsia in 2023.
- Postprandial distress syndrome represented the largest proportion of type-specific cases in France in 2023, accounting for approximately 60% of all cases.
- The 18–34 age group accounted for approximately 719,000 Functional Dyspepsia cases in Japan in 2023.
- In 2023, antiemetics represented around 20% of the therapeutic market in the United States.
- The Functional Dyspepsia Companies such as Daewoong Pharmaceutical Co Ltd , ISOThrive Inc , Mitsubishi Tanabe Pharma Corp , RaQualia Pharma Inc , Renexxion LLC , Zeria Pharmaceutical Co Ltd., and others
- The only approved Functional Dyspepsia drug, ACOFIDE (Acotiamide), was first approved in Japan in 2013 and remains the sole therapy specifically indicated for the condition.
Stay ahead in the Functional Dyspepsia Therapeutics Market with DelveInsight’s Strategic Report @ Functional Dyspepsia Treatment Drugs
Functional Dyspepsia Epidemiology Segmentation in the 7MM
- Prevalent Cases of Functional Dyspepsia
- Type-specific Cases of Functional Dyspepsia
- Age-specific Cases of Functional Dyspepsia
- Gender-specific Cases of Functional Dyspepsia
Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends @ Functional Dyspepsia Market Insights
Functional Dyspepsia Marketed Drugs
- ACOFIDE (Acotiamide): Astellas Pharma & Zeria Pharmaceuticals
ACOFIDE (acotiamide hydrochloride hydrate) is an oral drug approved for the treatment of Functional Dyspepsia with symptoms of postprandial fullness, upper abdominal bloating, and early satiation. As an acetylcholinesterase (AChE) inhibitor, acotiamide suppresses the degradation of acetylcholine (ACh) released from cholinergic nerve terminals, thereby enhancing gastric motility in Functional Dyspepsia patients. It was first approved in Japan in 2013 and remains approved exclusively there.
Functional Dyspepsia Market Outlook
Functional Dyspepsia is a chronic digestive disorder marked by persistent or recurrent upper abdominal pain and discomfort without an identifiable organic cause, affecting an estimated 10–30% of the population and representing the most common functional gastrointestinal disorder (FGID). Management is primarily symptomatic, given the condition’s relapsing and remitting pattern, with treatment options including proton pump inhibitors, H2-receptor antagonists, prokinetic agents, and antidepressants; testing and treating for Helicobacter pylori is also recommended when applicable. The pipeline remains notably underdeveloped, reflecting the lack of clear understanding of the disorder’s pathogenesis, though emerging herbal and prokinetic candidates such as AFIF and long-term data on itopride point toward incremental advances in symptom management.
Get In-Depth Knowledge on Functional Dyspepsia Market Trends and Forecasts with DelveInsight @ Functional Dyspepsia Treatment Market
Scope of the Functional Dyspepsia Market Report
- Coverage- 7MM
- Study Period- 2020–2034
- Forecast Period- 2024–2034
- Functional Dyspepsia Companies- Daewoong Pharmaceutical Co Ltd , ISOThrive Inc , Mitsubishi Tanabe Pharma Corp , RaQualia Pharma Inc , Renexxion LLC , Zeria Pharmaceutical Co Ltd., and others
- Functional Dyspepsia Therapies- ACOFIDE, and others in development including AFIF and itopride
- Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia Current Marketed and Emerging Therapies
- Functional Dyspepsia Market Dynamics: Functional Dyspepsia Market Drivers and Barriers
Unlock Strategic Insights with DelveInsight’s Comprehensive Functional Dyspepsia Market Report @ Functional Dyspepsia Market Drivers and Barriers
Table of Content
- Key Insights
- Report Introduction
- Executive Summary of Functional Dyspepsia
- Key Events
- Functional Dyspepsia Epidemiology and Market Forecast Methodology
- Functional Dyspepsia Market Overview at a Glance
- Disease Background and Overview: Functional Dyspepsia
- Treatment and Management
- Epidemiology and Patient Population of Functional Dyspepsia in the 7MM
- Patient Journey
- Key Endpoints in Functional Dyspepsia
- Marketed Therapies
- Functional Dyspepsia: Seven Major Market Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
